Patents Represented by Attorney, Agent or Law Firm Steven M. Odre
  • Genes encoding telomerase protein 1
    Patent number: 5981707
    Abstract: Disclosed are nucleic acid molecules encoding polypeptides that specifically bind telomerase RNA. Also disclosed are methods of preparing the nucleic acid molecules and polypeptides, and methods of using these molecules.
    Type: Grant
    Filed: April 15, 1998
    Date of Patent: November 9, 1999
    Assignees: Amgen Inc., Amgen Canada Inc.
    Inventors: Lea Anne Harrington, Murray O. Robinson
  • Methods for retreatment of patients afflicted with Hepatitis C using consensus interferon
    Patent number: 5980884
    Abstract: Methods for the retreatment, using a therapeutically effective amount of interferon consensus, of patients with HCV who exhibit serum ALT values above the upper limit of normal after previous treatment with interferon.
    Type: Grant
    Filed: February 5, 1996
    Date of Patent: November 9, 1999
    Assignee: Amgen, Inc.
    Inventors: Larry Blatt, Michael Klein
  • Cyclin E genes and proteins
    Patent number: 5973119
    Abstract: Disclosed are nucleic acid molecules encoding novel cyclin E2 polypeptides. Also disclosed are methods of preparing the nucleic acid molecules and polypeptides, and methods of using these molecules.
    Type: Grant
    Filed: June 5, 1998
    Date of Patent: October 26, 1999
    Assignee: Amgen Inc.
    Inventors: Steven Roy Coats, Michael Brian Bass, Murray O. Robinson
  • Therapeutic uses of keratinocyte growth factor
    Patent number: 5965530
    Abstract: Based on extensive in vivo studies in animals, it has now been discovered that KGF stimulates proliferation, growth and differentiation in various cells of epithelial tissue, besides keratinocytes. This better understanding of the biological effects of KGF in vivo enables the use of this polypeptide as a therapeutic agent, suitably formulated in a pharmaceutical composition, for the specific treatment of disease states and medical conditions afflicting tissues and organs such as the dermal adnexae, the liver, the lung, and the gastrointestinal tract.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: October 12, 1999
    Assignee: Amgen Inc.
    Inventors: Glenn Francis Pierce, Regina Mae Housley, Charles Frederick Morris
  • Peptides capable of modulating inflammatory heart disease
    Patent number: 5962636
    Abstract: Disclosed are novel peptides that modulate inflammatory heart disease. Also disclosed are DNA molecules encoding the peptides, and methods of making the peptides.
    Type: Grant
    Filed: August 12, 1998
    Date of Patent: October 5, 1999
    Assignee: Amgen Canada Inc.
    Inventors: Kurt Bachmaier, Andrew John Hessel, Nickolaus Neu, Josef Martin Penninger
  • Analogs of macrophage stimulating protein
    Patent number: 5948892
    Abstract: MSP analogs which have increased heterodimer formation and enhanced biological activity compared recombinant MSP are provided. The analogs are constructed by substituting unpaired cysteine residues which may interfere with interchain disulfide bonding. DNA sequences encoding MSP analogs, vectors and host cells for the expression of MSP analogs, and pharmaceutical compositions are also provided. The analogs may be used to treat conditions treatable by MSP such as gastrointestinal or hematopoietic disorders.
    Type: Grant
    Filed: December 16, 1996
    Date of Patent: September 7, 1999
    Assignee: Amgen Inc.
    Inventor: Robert C. Wahl
  • Use of hydrophobic interaction chromatography to purify polyethylene glycols
    Patent number: 5935564
    Abstract: The present invention relates to a process for purifying polyethylene glycols (PEGs) which utilizes hydrophobic interaction chromatography (HIC) to separate the PEGs based on their size and on their end-group functionality. The purified PEGs can be used to modify biologically active molecules and improve overall production of such molecules.
    Type: Grant
    Filed: September 18, 1997
    Date of Patent: August 10, 1999
    Assignee: Amgen Inc.
    Inventor: James Ervin Seely
  • Glial cell line-derived neurotrophic factor antibody
    Patent number: 5935795
    Abstract: A novel neurotrophic factor referred to as glial cell line-derived neurotrophic factor (GDNF) has been identified and isolated from serum free growth conditioned medium of B49 glioblastoma cells. Rat and human genes encoding GDNF have been cloned and sequenced. A gene encoding GDNF has been subcloned into a vector and the vector has been used to transform a host cell in order to produce biologically active GDNF in a recombinant DNA process. Antibodies to GDNF are disclosed, as well as methods for identifying members of the GDNF family of neurotrophic factors.
    Type: Grant
    Filed: May 26, 1995
    Date of Patent: August 10, 1999
    Assignee: Amgen Inc.
    Inventors: Leu-Fen H. Lin, Franklin D. Collins, Daniel H. Doherty, Jack Lile, Susan Bektesh
  • Method for treating Schwann and colon cells in vitro
    Patent number: 5929032
    Abstract: The survival and proliferation of Schwann cells can be promoted by culturing such cells in the presence of peptides derived from the EGF-like domain of proteins from the NDF/heregulin family. Colon epithelial cells can be stimulated to multiply and differentiate by culturing such cells in the presence of the same peptides.
    Type: Grant
    Filed: December 5, 1996
    Date of Patent: July 27, 1999
    Assignee: Amgen Inc.
    Inventors: Josette Fran.cedilla.oise Carnahan, Shinichi Hara, Hsieng Sen Lu, John Philip Mayer, Steven Kiyoshi Yoshinaga
  • Method for preventing and treating sensorineural hearing loss and vestibular disorders using glial cell line-derived neurotrophic factor(GDNF) protein product
    Patent number: 5929041
    Abstract: The present invention relates generally to methods for preventing and/or treating injury or degeneration of cochlear (and vestibular) hair cells and spiral ganglion neurons (as well as vestibular neurons--Carpa's neurons) by administering glial cell line-derived neurotrophic factor (GDNF). The invention relates more specifically to methods for treating sensorineural hearing loss and vestibular disorders.
    Type: Grant
    Filed: September 13, 1996
    Date of Patent: July 27, 1999
    Assignee: Amgen Inc.
    Inventor: Ella Magal
  • Methods of purifying hematopoietic cells using an antibody to a stem cell factor receptor
    Patent number: 5922847
    Abstract: The present invention relates to monoclonal antibodies specific for a cell receptor specific for human stem cell factor (hSCF) as well as pharmaceutical compositions containing such monoclonal antibodies and uses of such monoclonal antibodies.
    Type: Grant
    Filed: June 7, 1994
    Date of Patent: July 13, 1999
    Assignee: Amgen Inc.
    Inventors: Virginia C. Broudy, Nancy Lin
  • Genes encoding telomerase protein 1
    Patent number: 5919656
    Abstract: Disclosed are nucleic acid molecules encoding polypeptides that specifically bind telomerase RNA. Also disclosed are methods of preparing the nucleic acid molecules and polypeptides, and methods of using these molecules.
    Type: Grant
    Filed: November 15, 1996
    Date of Patent: July 6, 1999
    Assignees: Amgen Canada Inc., Amgen Inc.
    Inventors: Lea Anne Harrington, Murray O. Robinson
  • Nucleic acid molecules encoding placental-derived growth factors
    Patent number: 5914251
    Abstract: Polypeptide growth factors, termed PDFs, are described which are derived from placental tissue and promote the proliferation, growth and survival of prostate cells and epithelial cells. Nucleic acid molecules encoding the polypeptides are also described which are useful in recombinant methods for the production of the polypeptides.
    Type: Grant
    Filed: October 22, 1996
    Date of Patent: June 22, 1999
    Assignee: Amgen Inc.
    Inventors: Catherine L. Farrell, Francis H. Martin, Rachel Yabkowitz
  • Chemical modification of proteins to improve biocompatibility and bioactivity
    Patent number: 5900404
    Abstract: The present invention broadly relates to chemical modification of biologically active proteins or analogs thereof. More specifically, the present invention describes novel methods for site-specific chemical modification of various proteins, and resultant compositions having improved biocompatibility and bioactivity.
    Type: Grant
    Filed: August 15, 1997
    Date of Patent: May 4, 1999
    Assignee: Amgen Inc.
    Inventors: Colin Gegg, Olaf Kinstler
  • Genes encoding LSIRF polypeptides
    Patent number: 5891666
    Abstract: Disclosed are nucleotide sequences encoding a novel polypeptide termed LSIRF. Also disclosed are methods of preparing the polypeptide and uses thereof.
    Type: Grant
    Filed: April 3, 1996
    Date of Patent: April 6, 1999
    Assignee: Amgen Canada Inc.
    Inventors: Toshifumi Matsuyama, Alex Grossman
  • Stem cell factor analog compositions and method
    Patent number: 5885962
    Abstract: The present invention relates to stem cell factor analog polypeptide compositions, and vectors, host cells, and processes for recombinant DNA production of the present stem cell factor analogs. Pharmaceutical compositions and methods of use are also disclosed.
    Type: Grant
    Filed: April 5, 1996
    Date of Patent: March 23, 1999
    Assignee: Amgen Inc.
    Inventor: Hsieng Lu
  • Progenitor B cell stimulating factor
    Patent number: 5874399
    Abstract: A progenitor B cell stimulating factor which promotes the formation of pre-B cells is described. DNA sequences encoding same and methods of production and purification of the factor are also disclosed. The factor is used in the treatment of hematopoietic disorders and in bone marrow transplantation.
    Type: Grant
    Filed: May 24, 1995
    Date of Patent: February 23, 1999
    Assignee: Amgen Inc.
    Inventor: Babru Bahan Samal
  • Mutagenized DNA molecules encoding modified subunit a of Cholera-toxin
    Patent number: 5874287
    Abstract: The development of subunits and subunit analogs of the cholera exotoxin by recombinant DNA techniques provides vaccine products that can retain their biological activity and immunogenicity, and can confer protection against disease challenge. Genetically-engineered modifications of the subunits result in products that retain immunogenicity, yet are reduced in, or are essentially free of, enzymatic activity associated with toxin reactogenicity.
    Type: Grant
    Filed: May 5, 1995
    Date of Patent: February 23, 1999
    Assignee: Amgen Inc.
    Inventors: W. Neal Burnette, Harvey R. Kaslow
  • Stable protein: phospholipid compositions and methods
    Patent number: 5874075
    Abstract: The invention relates to stable compositions of proteins and related methods wherein a protein capable of transitioning into the molten globular state is contacted with a negatively charged lipid vesicle, thereby stabilizing the protein against thermally-induced aggregation, denaturation, and loss of activity. The protein:phospholipid complex directly stabilizes the secondary and tertiary structure of the protein, and the compositions are useful in high temperature formulations and in novel delivery vehicles.
    Type: Grant
    Filed: March 31, 1995
    Date of Patent: February 23, 1999
    Assignee: Amgen Inc.
    Inventors: David Collins, Younsik Cha, David Brems
  • Anti-inflammatory CD14 polypeptides
    Patent number: 5869055
    Abstract: The invention relates to anti-inflammatory polypeptides comprising soluble CD14 related polypeptides having amino acids at position 7-10 that are different from the native sequence or having amino acids 1-14 deleted.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: February 9, 1999
    Assignee: Amgen, Inc.
    Inventors: Shao-Chieh Juan, Henri S. Lichenstein, Samuel D. Wright